Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1-S Transition.
Buck SAJ, Van Hemelryk A, de Ridder C, Stuurman D, Erkens-Schulze S, van 't Geloof S, Teubel WJ, Koolen SLW, Martens-Uzunova ES, van Royen ME, de Wit R, Mathijssen RHJ, van Weerden WM. Buck SAJ, et al. Among authors: de ridder c, de wit r. Mol Cancer Ther. 2024 May 2;23(5):711-720. doi: 10.1158/1535-7163.MCT-23-0420. Mol Cancer Ther. 2024. PMID: 38030379
Danusertib, an aurora kinase inhibitor.
Meulenbeld HJ, Mathijssen RH, Verweij J, de Wit R, de Jonge MJ. Meulenbeld HJ, et al. Among authors: de wit r, de jonge mj. Expert Opin Investig Drugs. 2012 Mar;21(3):383-93. doi: 10.1517/13543784.2012.652303. Epub 2012 Jan 13. Expert Opin Investig Drugs. 2012. PMID: 22242557 Review.
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM. van Soest RJ, et al. Among authors: de wit r, de morree es. Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24. Eur J Cancer. 2013. PMID: 24200698
Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015.
van Soest RJ, de Wit R, van Weerden WM. van Soest RJ, et al. Among authors: de wit r. Eur Urol. 2014 Oct;66(4):e71-2. doi: 10.1016/j.eururo.2014.06.038. Epub 2014 Jul 8. Eur Urol. 2014. PMID: 25012524 No abstract available.
Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
van Soest RJ, de Morrée ES, Kweldam CF, de Ridder CMA, Wiemer EAC, Mathijssen RHJ, de Wit R, van Weerden WM. van Soest RJ, et al. Among authors: de wit r, de morree es, de ridder cma. Eur Urol. 2015 Jun;67(6):981-985. doi: 10.1016/j.eururo.2014.11.033. Epub 2014 Dec 4. Eur Urol. 2015. PMID: 25484141
Inter-patient variability in docetaxel pharmacokinetics: A review.
Nieuweboer AJ, de Morrée ES, de Graan AJ, Sparreboom A, de Wit R, Mathijssen RH. Nieuweboer AJ, et al. Among authors: de wit r, de morree es, de graan aj. Cancer Treat Rev. 2015 Jul;41(7):605-13. doi: 10.1016/j.ctrv.2015.04.012. Epub 2015 May 7. Cancer Treat Rev. 2015. PMID: 25980322 Review.
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.
Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S. Onstenk W, et al. Among authors: de wit r, de laere b. Eur Urol. 2015 Dec;68(6):939-45. doi: 10.1016/j.eururo.2015.07.007. Epub 2015 Jul 15. Eur Urol. 2015. PMID: 26188394 Clinical Trial.
470 results